Cantargia, a Sweden-based biopharmaceutical company backed by life sciences business Lubio Science, has filed an initial public offering on the Nasdaq North First market in Stockholm, Sweden.
The company plans to raise an initial SEK 44.1m ($5.4m) from the share issue, which would be increased to more than $12.2m if additional option rights are taken up.
Cantargia develops antibody-based treatments for leukemia that are able to attack both cancer stem cells and mature cancer cells, and is a spin-out of…
